📰 Pascal Touchon News
Page 7 - Pascal Touchon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Touchon. Real-time updates on events, politics, business and more.
December 19, 2022
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), and Pierre Fabre today announced that the European Commission (EC) has granted marketing...
December 19, 2022
19.12.2022 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two ... Seite 1
December 8, 2022
/PRNewswire/ -- Dantari, Inc. ("Dantari"), a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers...
November 21, 2022
Thousand Oaks-based Atara Biotherapeutics reported a loss of $84.1 million in its third-quarter earnings report.
October 14, 2022
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission
October 14, 2022
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European
October 14, 2022
/PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the...
September 28, 2022
Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines
July 15, 2022
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Wednesday, MarketBeat.com reports. They currently have a $10.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside […]
July 13, 2022
 Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment  IDSMC Did Not Identify Any Safety ConcernsPhase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDTSOUTH...